Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not

Warren Fingrut, BSc, MD, Arjun Law, MD DM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Rajat Kumar, MD, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Dennis Dong Hwan Kim, MD

Blood (2018) 132 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2018-99-113938

Published: 2018

Journal Articles

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

Maria Rhida Bautista, MD FRACP, FRCPA, Arjun Law, MD DM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Rajat Kumar, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2018-99-119472

Published: 2018

Journal Articles

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Mohammed A. Marei, Eshetu G Atenafu, MSc, P.Stat, Arjun Law, MD DM, Wilson Lam, MD, Rajat Kumar, MD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Dennis Dong Hwan Kim, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Fotios V. Michelis, MD PhD

Blood (2018) 132 (Supplement 1): 4670.

https://doi.org/10.1182/blood-2018-99-113884

Published: 2018

Journal Articles

Efficacy of Cidofovir in Treatment of BK Virus Induced Hemorrhagic Cystitis in Post Allogeneic Hematopoietic Cell Transplant Recipients

Eric Anthony Coomes, MD, Amanda Jacques, BScPharm, RPh, ACPR, Fotios V. Michelis, MD PhD, Dennis (Dong-Hwong) Kim, MD PhD, Santhosh Thyagu, MD, Auro Viswabandya, MDMDcine,DM Clinical Hematology, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Uday Deotare, MD

Blood (2017) 130 (Supplement 1): 5479.

https://doi.org/10.1182/blood.V130.Suppl_1.5479.5479

Published: 2017

Journal Articles

Pre-Transplant Pulmonary Function Test Parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in Combination Can Predict the Risk for Development of Lung Gvhd after Allogeneic Transplantation

Wilson Lam, MD, Arjun Datt Law, MBBS, MD DM, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD, Auro Viswabandya, MDMDcine,DM Clinical Hematology, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Theodore Marras, MD MSc, Shikha Mittoo, MD MHS, Dennis Kim, MD

Blood (2017) 130 (Supplement 1): 1973.

https://doi.org/10.1182/blood.V130.Suppl_1.1973.1973

Published: 2017

Journal Articles

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 5781.

https://doi.org/10.1182/blood.V128.22.5781.5781

Published: 2016

Journal Articles

Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience

Hassan A. Aljasem, MBBS, MD, Hans A. Messner, MD PhD, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Auro Viswabandya, MD DM, Santhosh Thyagu, MBBS, MD DM, Uday Deotare, MD DM, Fotios V. Michelis, MD PhD

Blood (2016) 128 (22): 5838.

https://doi.org/10.1182/blood.V128.22.5838.5838

Published: 2016

Journal Articles

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 3430.

https://doi.org/10.1182/blood.V128.22.3430.3430

Published: 2016

Journal Articles

Comprehensive Analysis of Pre-Transplant Pulmonary Function Test Parameters Including FEV1, FVC, DLco, FEF50%/75%, Frc, RV and TLC As Prognostic Factors for Long-Term Outcomes after Allogeneic Transplantation

Wilson Lam, MD, Uday Deotare, MD DM, Jeffrey H. Lipton, MD PhD, Theodore Marras, MD MSc, Hans A. Messner, MD PhD, Fotios V. Michelis, MD PhD, Shikha Mittoo, MD MHS, Santhosh Thyagu, MBBS, MD DM, Auro Viswabandya, MD DM, Dennis Dong Hwan Kim, MD PhD

Blood (2016) 128 (22): 2253.

https://doi.org/10.1182/blood.V128.22.2253.2253

Published: 2016

Journal Articles

Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies

Manar Mohamed Ibrahim Khalil, MD MBBS, MRCP, Hans A. Messner, MD PhD, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Auro Viswabandya, MD DM, Santhosh Thyagu, MBBS, MD DM, Uday Deotare, MD DM, Fotios V. Michelis, MD PhD

Blood (2016) 128 (22): 4652.

https://doi.org/10.1182/blood.V128.22.4652.4652

Published: 2016

Journal Articles

Risk Factor Analysis for the Development of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation: Randomized Stratification and Propensity Score Analysis

Marc Poch Martell, MD, Elizabeth Shin, Jieun Uhm, MD, Fotios V. Michelis, MDPhD, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD/PhD, Dennis Dong Hwan Kim, MDPhD

Blood (2015) 126 (23): 1945.

https://doi.org/10.1182/blood.V126.23.1945.1945

Published: 2015

Journal Articles

Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

Samantha J Mayo, RN, PhD, Hans A. Messner, MD/PhD, Sean B. Rourke, PhD, Doris Howell, RN PhD, J. Charles Victor, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Vikas Gupta, MD MRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, Laura McGillis, BScN, MN, RN(EC), CONc, Jieun Uhm, MD, Fotios V. Michelis, MDPhD, Naheed Alam, MBBS,MD, Anna Lambie, RN NP, Dawn Breen, RN, David Loach, MD, Christine Piescic, RN, Kelly Metcalfe, RN PhD

Blood (2015) 126 (23): 3289.

https://doi.org/10.1182/blood.V126.23.3289.3289

Published: 2015

Journal Articles

Analysis of Impact of Comorbidities Constituting the HCT-CI Score on the Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia

Fotios V. Michelis, MDPhD, Hans A. Messner, MD/PhD, Naheed Alam, MBBS,MD, Vikas Gupta, MD MRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, John Kuruvilla, MD, Anna Lambie, RN NP, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 3201.

https://doi.org/10.1182/blood.V126.23.3201.3201

Published: 2015

Journal Articles

Propensity Score Matching Analysis Comparing Azathioprine Plus Prednisone Vs Prednisone Alone Regimens As First-Line Treatment in Chronic Graft-Versus-Host Disease

Jieun Uhm, MD, Elizabeth Shin, Fotios V. Michelis, MDPhD, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD/PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2015) 126 (23): 3126.

https://doi.org/10.1182/blood.V126.23.3126.3126

Published: 2015

Journal Articles

Donor Type, Chronic Gvhd Subtype , and the Severity of Chronic Gvhd at the Time of Initiation of Chronic Gvhd Treatment Affect Failure-Free Survival in the Patients with Chronic Gvhd

Jieun Uhm, MD, Elizabeth Shin, Marc Poch Martell, MD, Fotios V. Michelis, MDPhD, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD/PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2015) 126 (23): 3139.

https://doi.org/10.1182/blood.V126.23.3139.3139

Published: 2015

Journal Articles

Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission

Fotios V. Michelis, MDPhD, Hans A. Messner, MD/PhD, Naheed Alam, MBBS,MD, Vikas Gupta, MD MRCP, FRCPath, Dennis Dong Hwan Kim, MD PhD, John Kuruvilla, MD, Anna Lambie, RN NP, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 2020.

https://doi.org/10.1182/blood.V126.23.2020.2020

Published: 2015

Journal Articles

Incidence and Risk Factors for Nontuberculous Mycobacteria Infection after Allogeneic Hematopoietic Cell Transplantation

Jennifer M. Beswick, BHSc, MD, Elizabeth Shin, Jieun Uhm, MD, Fotios V. Michelis, MDPhD, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD/PhD, Theodore Marras, MD MSc, Dennis Dong Hwan Kim, MD PhD

Blood (2015) 126 (23): 1917.

https://doi.org/10.1182/blood.V126.23.1917.1917

Published: 2015

Journal Articles

Incidence and Risk Factors for Vzv Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion

Sita D. Bhella, MD, Elizabeth Shin, Marc Poch Martell, MD, Jieun Uhm, MD, Fotios V. Michelis, MDPhD, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD/PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2015) 126 (23): 1921.

https://doi.org/10.1182/blood.V126.23.1921.1921

Published: 2015

Journal Articles

Product Attributes and Donor Factors in Reported Cases of Transfusion-Associated Graft Versus Host Disease: A Systematic Review

Ilana Kopolovic, MD, Jackie Ostro, MD, Christine Cserti, MD, Walter Sunny Dzik, MD, Hidacki Tsubota, MD, Amy Keir, MD, Hans A. Messner, MD PhD, Neal denHollander, MD, Yulia Lin, MD, Jeannie Callum, MD

Blood (2014) 124 (21): 2883.

https://doi.org/10.1182/blood.V124.21.2883.2883

Published: 2014

Journal Articles

Systematic Review of Cases of Transfusion Associated Graft-Versus-Host-Disease (TA-GVHD): Analysis of Patient Characteristics and Outcomes

Jackie Ostro, MD, Ilana Kopolovic, MD, Yulia Lin, MD, Walter H. Dzik, MD, Christine Cserti, MD, Hideki Tsubota, Amy Keir, MD, Hans A. Messner, MD/PhD, Neal DenHollander, PhD, Jeannie Callum, MD

Blood (2014) 124 (21): 2885.

https://doi.org/10.1182/blood.V124.21.2885.2885

Published: 2014

NARROW

High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Efficacy of Cidofovir in Treatment of BK Virus Induced Hemorrhagic Cystitis in Post Allogeneic Hematopoietic Cell Transplant Recipients

Pre-Transplant Pulmonary Function Test Parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in Combination Can Predict the Risk for Development of Lung Gvhd after Allogeneic Transplantation

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Comprehensive Analysis of Pre-Transplant Pulmonary Function Test Parameters Including FEV1, FVC, DLco, FEF50%/75%, Frc, RV and TLC As Prognostic Factors for Long-Term Outcomes after Allogeneic Transplantation

Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies

Risk Factor Analysis for the Development of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation: Randomized Stratification and Propensity Score Analysis

Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

Analysis of Impact of Comorbidities Constituting the HCT-CI Score on the Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia

Propensity Score Matching Analysis Comparing Azathioprine Plus Prednisone Vs Prednisone Alone Regimens As First-Line Treatment in Chronic Graft-Versus-Host Disease

Donor Type, Chronic Gvhd Subtype , and the Severity of Chronic Gvhd at the Time of Initiation of Chronic Gvhd Treatment Affect Failure-Free Survival in the Patients with Chronic Gvhd

Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission

Incidence and Risk Factors for Nontuberculous Mycobacteria Infection after Allogeneic Hematopoietic Cell Transplantation

Incidence and Risk Factors for Vzv Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion

Product Attributes and Donor Factors in Reported Cases of Transfusion-Associated Graft Versus Host Disease: A Systematic Review

Systematic Review of Cases of Transfusion Associated Graft-Versus-Host-Disease (TA-GVHD): Analysis of Patient Characteristics and Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only